Randomized Controlled Trial of Alert-Based Computerized Decision Support for Patients With Peripheral Artery Disease Not Prescribed Lipid-Lowering Therapy
Status: Recruiting
Location: See location...
Intervention Type: Behavioral
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
This single-center, 400-patient, randomized controlled trial assesses the impact of a patient- and provider-facing EPIC Best Practice Advisory (BPA; alert-based computerized decision support tool) to increase guideline-directed utilization of statin and statin-alternative oral LDL-C lowering therapies in patients with PAD who are not being prescribed LDL-C-lowering therapy.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• All patients ≥ 18 years old
• Seen in Cardiovascular Medicine Clinic, Primary Care, Podiatry, Vascular Surgery, and Diabetology
• Medical history entry, visit diagnosis, or problem list entry of PAD
• Not prescribed LDL-C-lowering therapy
Locations
United States
Massachusetts
Brigham and Women's Hospital
RECRUITING
Boston
Contact Information
Primary
Gregory Piazza
gpiazza@bwh.harvard.edu
6177326984
Backup
Candrika D Kharaini
cdkhairani@@bwh.harvard.edu
6177326984
Time Frame
Start Date: 2023-03-01
Estimated Completion Date: 2026-07-30
Participants
Target number of participants: 400
Treatments
Experimental: Alert
Alert-based CDS will consist of an on-screen electronic alert that will notify the clinician that the patient has an indication for LDL-C-lowering therapy but is not prescribed any. The clinician will have the opportunity to proceed to an order template through which appropriate lipid-lowering can be prescribed. The clinician could also elect to learn more about current evidence-based recommendations for LDL-C lowering in the PAD population. Finally, the clinician could elect to proceed without ordering oral LDL-C-lowering therapy or reading evidence-based recommendations for LDL-C lowering but would have to provide a rationale for not doing so.
No_intervention: No Alert
No on-screen notification will be issued to the clinician
Related Therapeutic Areas
Sponsors
Leads: Brigham and Women's Hospital
Collaborators: Esperion Therapeutics, Inc.